Geneva Advisors’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Geneva Advisors’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$676K	Sell	13,650 -756	-5%	-$39.6K	0.01%	442
2017 Q1	$789K	Buy	14,406 +293	+2%	+$15.5K	0.01%	405
2016 Q4	$786K	Buy	14,113 +56	+0.4%	+$2.69K	0.02%	397
2016 Q3	$642K	Sell	14,057 -15	-0.1%	-$602	0.01%	423
2016 Q2	$562K	Buy	14,072 +755	+6%	+$27.7K	0.01%	419
2016 Q1	$464K	Sell	13,317 -3,892	-23%	-$143K	0.01%	444
2015 Q4	$739K	Sell	17,209 -2,671	-13%	-$134K	0.01%	347
2015 Q3	$866K	Sell	19,880 -8,155	-29%	-$440K	0.02%	308
2015 Q2	$1.45M	Buy	28,035 +7,048	+34%	+$301K	0.03%	252
2015 Q1	$822K	Buy	20,987 +3,071	+17%	+$120K	0.01%	337
2014 Q4	$692K	Buy	17,916 +1,047	+6%	+$39.9K	0.01%	354
2014 Q3	$595K	Buy	16,869 +2,933	+21%	+$86.1K	0.01%	393
2014 Q2	$376K	Sell	13,936 -6,957	-33%	-$181K	0.01%	481
2014 Q1	$542K	Buy	+20,893	New	+$501K	0.01%	377

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Geneva Advisors's BSTC Position: Q2 2017 in Review

Geneva Advisors reduced its BioSpecifics Technologies Corp. (BSTC) stake by 5.2% in Q2 2017, selling an estimated $39.6K and leaving 13,650 shares worth $676K. The position accounts for 0.01% of the portfolio, ranked #442.

Geneva Advisors first reported a position in BSTC in Q1 2014 and has held it in 14 quarters since. The position peaked at $1.45M in Q2 2015. 90 funds tracked by Wall St. Rank hold BSTC as of Q2 2017.

Geneva Advisors held 13,650 shares of BioSpecifics Technologies Corp. worth $676K as of Q2 2017.
Geneva Advisors sold 756 BioSpecifics Technologies Corp. shares in Q2 2017, an estimated $39.6K.
BioSpecifics Technologies Corp. made up 0.01% of Geneva Advisors's portfolio in Q2 2017, its #442 holding.
Geneva Advisors first reported a position in BioSpecifics Technologies Corp. in Q1 2014 and has held it in 14 quarters since.
Geneva Advisors's BioSpecifics Technologies Corp. position peaked at $1.45M in Q2 2015.
90 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.